C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement
Copyright © 2024 Q32 Bio. Published by Elsevier Inc. All rights reserved..
Complement-mediated diseases can be treated using systemic inhibitors. However, complement components are abundant in circulation, affecting systemic inhibitors' exposure and efficacy. Furthermore, because of complement's essential role in immunity, systemic treatments raise infection risk in patients. To address these challenges, we developed antibody fusion proteins combining the alternative-pathway complement inhibitor factor H (fH1-5) with an anti-C3d monoclonal antibody (C3d-mAb-2fH). Because C3d is deposited at sites of complement activity, this molecule localizes to tissue complement while minimizing circulating complement engagement. These fusion proteins bind to deposited complement in diseased human skin sections and localize to activated complement in a primate skin injury model. We further explored the pharmacology of C3d-mAb-2fH proteins in rodent models with robust tissue complement activation. Doses of C3d-mAb-2fH >1 mg/kg achieved >75% tissue complement inhibition in mouse and rat injury models while avoiding circulating complement blockade. Glomerular-specific complement inhibition reduced proteinuria and preserved podocyte foot-process architecture in rat membranous nephropathy, indicating disease-modifying efficacy. These data indicate that targeting local tissue complement results in durable and efficacious complement blockade in skin and kidney while avoiding systemic inhibition, suggesting broad applicability of this approach in treating a range of complement-mediated diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Molecular therapy : the journal of the American Society of Gene Therapy - 32(2024), 4 vom: 03. Apr., Seite 1061-1079 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Fei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
80295-45-0 |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ymthe.2024.02.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368725456 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368725456 | ||
| 003 | DE-627 | ||
| 005 | 20240408232417.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ymthe.2024.02.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM368725456 | ||
| 035 | |a (NLM)38382529 | ||
| 035 | |a (PII)S1525-0016(24)00070-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Fei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Q32 Bio. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Complement-mediated diseases can be treated using systemic inhibitors. However, complement components are abundant in circulation, affecting systemic inhibitors' exposure and efficacy. Furthermore, because of complement's essential role in immunity, systemic treatments raise infection risk in patients. To address these challenges, we developed antibody fusion proteins combining the alternative-pathway complement inhibitor factor H (fH1-5) with an anti-C3d monoclonal antibody (C3d-mAb-2fH). Because C3d is deposited at sites of complement activity, this molecule localizes to tissue complement while minimizing circulating complement engagement. These fusion proteins bind to deposited complement in diseased human skin sections and localize to activated complement in a primate skin injury model. We further explored the pharmacology of C3d-mAb-2fH proteins in rodent models with robust tissue complement activation. Doses of C3d-mAb-2fH >1 mg/kg achieved >75% tissue complement inhibition in mouse and rat injury models while avoiding circulating complement blockade. Glomerular-specific complement inhibition reduced proteinuria and preserved podocyte foot-process architecture in rat membranous nephropathy, indicating disease-modifying efficacy. These data indicate that targeting local tissue complement results in durable and efficacious complement blockade in skin and kidney while avoiding systemic inhibition, suggesting broad applicability of this approach in treating a range of complement-mediated diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a C3d | |
| 650 | 4 | |a complement | |
| 650 | 4 | |a factor H | |
| 650 | 4 | |a glomerular disease | |
| 650 | 4 | |a skin disease | |
| 650 | 4 | |a tissue-targeted | |
| 650 | 7 | |a Complement Factor H |2 NLM | |
| 650 | 7 | |a 80295-65-4 |2 NLM | |
| 650 | 7 | |a Complement C3d |2 NLM | |
| 650 | 7 | |a 80295-45-0 |2 NLM | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 700 | 1 | |a Ryan, Sarah T |e verfasserin |4 aut | |
| 700 | 1 | |a Fahnoe, Kelly C |e verfasserin |4 aut | |
| 700 | 1 | |a Morgan, Jennifer G |e verfasserin |4 aut | |
| 700 | 1 | |a Cheung, Anne E |e verfasserin |4 aut | |
| 700 | 1 | |a Storek, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Best, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Hui A |e verfasserin |4 aut | |
| 700 | 1 | |a Locatelli, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Shuyun |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Enno |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt-Jiménez, Leon F |e verfasserin |4 aut | |
| 700 | 1 | |a Bieber, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Henderson, Joel M |e verfasserin |4 aut | |
| 700 | 1 | |a Lian, Christine G |e verfasserin |4 aut | |
| 700 | 1 | |a Verschoor, Admar |e verfasserin |4 aut | |
| 700 | 1 | |a Ludwig, Ralf J |e verfasserin |4 aut | |
| 700 | 1 | |a Benigni, Ariela |e verfasserin |4 aut | |
| 700 | 1 | |a Remuzzi, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Salant, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Kalled, Susan L |e verfasserin |4 aut | |
| 700 | 1 | |a Thurman, Joshua M |e verfasserin |4 aut | |
| 700 | 1 | |a Holers, V Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Violette, Shelia M |e verfasserin |4 aut | |
| 700 | 1 | |a Wawersik, Stefan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular therapy : the journal of the American Society of Gene Therapy |d 2000 |g 32(2024), 4 vom: 03. Apr., Seite 1061-1079 |w (DE-627)NLM108239381 |x 1525-0024 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2024 |g number:4 |g day:03 |g month:04 |g pages:1061-1079 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ymthe.2024.02.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2024 |e 4 |b 03 |c 04 |h 1061-1079 | ||